Q-omics provides the consensus-scored ZNF420 profile across patient tissues and cancer cell-line models. ZNF420 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF420 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF420 RNA expression shows 21,025 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where ZNF420 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF420 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF420 survival associations across molecular data types. ZNF420 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF420 RNA expression–survival associations across cancer types. High ZNF420 expression shows unfavorable associations in LIHC and LGG, but favorable associations in KIRC, UCS, BRCA and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF420 RNA expression.
This table summarizes ZNF420 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF420. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF420 shows lower tumor expression in THCA and HNSC and higher tumor expression in LUAD, LIHC, BRCA and CHOL. The THCA box plot shows higher ZNF420 RNA expression in normal versus tumor tissue (log2 FC = −1.112, t-test p < 0.001).
This table shows molecular features associated with ZNF420 in patient tissues and cancer cell lines. In patient samples, ZNF420 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF420 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
